FDA Approves New Animal Drug for Dogs with Adrenal Insufficiency

Summary

The FDA is updating its regulations to reflect the approval of a new animal drug application by Novartis Animal Health US, Inc. for the use of desoxycorticosterone pivalate to treat mineralocorticoid deficiency in dogs with primary adrenocortical insufficiency.